Imexhs Ltd · ASX:IME
Imexhs — Investor Presentation (August 2022)
35 slides from Imexhs's investor presentation, Aug 3, 2022
Slide 1: Investor Presentation Capital Raising
Investor Presentation Capital Raising 3 August 2022
Slide 2: Disclaimer
Disclaimer Disclaimer This presentation has been prepared by, and is the sole responsibility of, IMEXHS Limited ACN 096 687 839 (the Company) and is dated 3 August 2022. The Company is under no obligation to update or keep the information represented in this presentation current past the date of pre
Slide 3: Disclaimer
Disclaimer No offer of securities Information contained in this presentation does not constitute an offer to sell or a solicitation of an offer to buy or sell Company securities in any jurisdiction. This presentation is not a prospectus, product disclosure document, or other offering document or con
Slide 4: Disclaimer
Disclaimer To the maximum extent permitted by law, the Company, the Lead Manager and their respective Associated Persons each expressly disclaims and excludes all liability that may arise from this presentation, or the use of or reliance on anything contained in or omitted from this presentation, or
Slide 5: Agenda
Agenda Q2 FY2022 Results and Capital Raising 1. IMEXHS Overview 2. 1H FY22 Results 3. Business Update 4. Outlook 5. Capital Raising 5
Slide 6: Overview
imexHSs Overview
Slide 7: Investment Highlights
Investment Highlights Contracted Strong pipeline of Strong year-on-year Annualised Recurring opportunities incl. growth across all key Revenue of $20.5m, two material near- metrics up 61% year on year term opportunities Business to reach Disruptive, Founder led and underlying EBITDA proprietary, clo
Slide 8: One Company with two businesses aimed at democratising access to medical expertise
One Company with two businesses aimed at democratising access to medical expertise Medical Imaging Software Radiology Services Provider of innovative, cloud-based, Outsourcing of imaging facilities AI medical imaging software and teleradiology to hospitals and solutions medical facilities 8
Slide 9: Our 10-year Journey
Our 10-year Journey Founded in Bogota, Colombia to provide access to medical technology in 2012 hard-to-reach areas 2015 Expanded into countries in Latin America such as Ecuador and Mexico 2018 Listed on the Australian Securities Exchange to expand our global presence 2019 Received FDA Clearance in
Slide 10: Software Services and Radiology Services footprint
Software Services 15 countries; 418 sites Colombia, Spain and Mexico 2,650+ radiologists 33 radiology centres 35 distributors in 15 countries 130+ in-house radiologists 37 engineers 10
Slide 11: 1H FY22 Results
imexHs 1H FY22 Results
Slide 12: 1H FY22 Financial Highlights
1H FY221 Financial Highlights Sales Revenue Annual Recurring EBITDA Revenue (ARR)2 Up 83% yoy $9.5m Up 61% yoy $20.5m vs ($2.1m) in FY21 ($0.5m) Up 82% on a constant Up 60% on a constant currency basis currency basis Recurring Closing cash Underlying revenue EBITDA3 Up 91% yoy $9.3m Vs $4.2m at 31 $
Slide 13: 1H FY22 Revenue and ARR Split
1H FY22 Revenue and ARR Split Medical • Software revenue primarily Radiology related to sales of AQUILA $M Software Total Services Enterprise Imaging • Radiology services includes Revenue1 2.8 6.7 9.5 RIMAB along with other services related to outsourcing radiology ARR2 8.5 12.0 20.5 on-premise or r
Slide 14: Business Update
ime «Hs Business Update
Slide 15: 1H FY22 Operational Highlights
1H FY22 Operational Highlights • IMEXHS Cloud (formerly AQUILA in the Cloud) 140 contracts signed to date with ARR of $2.8m • Signed 6 new partners from 4 different countries and signed 2 new Master Distributors - Crowd IT in Australia and 3verest in the UK. • Entered Thai market with FDA registrati
Slide 16: Path to Profitability
Path to Profitability • Cost out program aimed at getting to cash positive at the company level with both divisions profitable • Development is directed towards near term profitable outcomes • Sales capability directed towards immediate pipeline • Maintaining current high medical and customer servic
Slide 17: Outlook
Outlook
Slide 18: FY22 Outlook
FY22 Outlook FY22 guidance • Initiatives to reach profitability and cashflow breakeven and • Revenue between $18.0m to maintaining the integrity of our 5- $20.5m (vs $13.4m in FY21) year strategic framework • Underlying1 EBITDA positive for • Strong and growing pipeline 2022 (vs loss of $1.4m in FY2
Slide 19: Capital Raising
ime «Hs Capital Raising
Slide 20: Details of the Offer
Details of the Offer Offer Structure and • A fully underwritten capital raising of approximately $4.0m, comprising: Size • A fully underwritten Placement of $2.0m, consisting of two parts: • Tranche 1 – an institutional placement to raise approximately $1.0m (“Institutional Placement”); and • Tranch
Slide 21: Indicative Timetable
Indicative Timetable INDICATIVE OFFER TIMETABLE Event 2022 Trading halt (pre-market open) Monday, 1 August Trading halt lifted – Shares recommence trading on ASX Wednesday, 3 August Record Date for Entitlement Offer 7.00pm (AEST) Monday, 8 August Settlement of first tranche Placement Tuesday, 9 Augu
Slide 22: Use of Proceeds & Capital Structure
Use of Proceeds & Capital Structure Sources $m Capital Structure $m Placement 2.0 Current Market Capitalisation at 29 July 2022 20.5 Entitlement Offer 2.0 Equity Raising 4.0 Total 4.0 Uses1 $m Pro forma cash2 (4.9) Working Capital and costs of equity raising 3.5 Pro forma debt2 1.5 Repayment of debt
Slide 23: Key Risks
Key Risks This section sets out some of the key risks associated with any investment in IMEXHS, which may affect the value of IMEXHS Shares. The risks set out below are not necessarily listed in order of importance and do not constitute an exhaustive list of all risks involved with an investment in
Slide 24: Key Risks
Key Risks Risk Description IMEXHS is currently undertaking a cost reduction program. There is a risk that, if this program is not implemented efficiently, it Implementation of cost may not deliver the anticipated benefits. The cost reduction program may also delay certain projects in development and
Slide 25: Key Risks
Key Risks Risk Description The future success of IMEXHS will depend on its ability to develop innovative solutions that keep pace with technological change, evolving industry standards and innovation in the medical imaging industry. There can be no certainty that the Company will be successful in ad
Slide 26: Key Risks
Key Risks Risk Description IMEXHS uses off-the-shelf software (in addition to its own proprietary software) to enable the functionality of its product offerings. This external software may be subject to issues outside of IMEXHS’s control such as third party interfaces, version External technology co
Slide 27: Key Risks
Key Risks Risk Description IMEXHS will need to continue to expand its operations if it successfully achieves market acceptance of its products and Ability to manage services in new markets. IMEXHS’s existing systems, procedures and resources may not be adequate to support such growth effectively exp
Slide 28: Key Risks
Key Risks Risk Description IMEXHS currently has employees in Colombia and Mexico and distributors engaged in Mexico and other Latin American countries. IMEXHS may wish to engage further employees and distributors outside of Australia as it grows its existing business Doing business and expands to ne
Slide 29: Summary of Underwriting Agreement
Summary of Underwriting Agreement IMEXHS Limited ACN 096 687 839 (IMEXHS) has entered into an underwriting agreement with Morgans Corporate Limited ACN 010 539 607 (Lead Manager), (Agreement) under which the Lead Manager has agreed to manage and underwrite the placement to institutional and sophisti
Slide 30: Summary of Underwriting Agreement
Summary of Underwriting Agreement Defective A statement in the Offer documentation (whether by omission or otherwise) is or becomes false, misleading or deceptive in a material documentation particular or is likely to mislead or deceive, or the documentation in respect of the Offer fails to comply w
Slide 31: Appendices
ime «Hs Appendices
Slide 32: 2025+ Endgame
2025+ Endgame Enterprise Imaging – Single – Medical Imaging platform RIS, PACS, VNA – – Cloud Technology Results Distribution Portal – Software – Multitenant Digital Pathology – Platform – DevOps Interoperability – – Onboarding automation Teleradiology – – SaaS / PaaS Business Model Multi-Department
Slide 33: 5-year Strategy Framework
5-year Strategy Framework 2026+ Cost saving initiatives announced will not have significant Harvesting impact on achieving milestones 10% Resource Allocation 2024 | 2025 Growing (Product Offering) IMEXHS Cloud 20% Resource Allocation • Single Unified Medical Imaging Single Software Software Platform
Slide 34: Disclaimer
Disclaimer Foreign selling restrictions New Zealand Shares are not being offered to the public within New Zealand other than to existing shareholders of the Company with registered addresses in New Zealand to whom the offer of these securities is being made in reliance on the Financial Markets Condu
Slide 35: Investor Presentation
Investor Presentation 3 August 2022